Source-grounded facts extracted from C4 Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Kendra R. Adams changed role as Chief Financial Officer, Head of Corporate Affairs and Treasurer at C4 Therapeutics, Inc..
“Kendra R. Adams, the Company's Chief Financial Officer, Head of Corporate Affairs and Treasurer, has been designated as the Company's principal accounting officer, effective May 15, 2026.”
Mark Mossler departed as Chief Accounting Officer at C4 Therapeutics, Inc..
“Mark Mossler will no longer serve as the Company's Chief Accounting Officer, effective May 15, 2026.”
C4 Therapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue $6.2 million, net income $25.1 million.
“Global Healthcare Conference taking place in Miami, FL from June 8 - 10, 2026. FIRST QUARTER 2026 FINANCIAL RESULTS Revenue: Total revenue for the first quarter of 2026 was $6.2 million, compared to $7.2 million for the first quarter of 2025. The decrease in revenue resulted from the conclusion of the research collaboration with Merck and the prioritization of”
C4 Therapeutics, Inc.: Amended bylaws to designate exclusive federal forum for Securities Act and Exchange Act claims, effective immediately (effective 2026-04-09).
“On April 9, 2026, the Board of Directors (the “Board”) of C4 Therapeutics, Inc. (the “Company”) approved an amendment to the Company’s second amended and restated by-laws (the “By-laws Amendment”), effective immediately, to designate the United States District Court for the District of Massachusetts and the United States District Court for the District of Delaware as the exclusive forums for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, the Securities Exchange Act of 1934, as amended, or the respective rules and regulations promulgated thereunder, unless the Company consents in writing to the selection of an alternative forum.”
C4 Therapeutics, Inc. entered into "License Agreement" with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (together, "Roche") valued at $20.0 million upfront, over $1.0 billion in aggregate milestone payments (effective 2026-04-08).
“On April 8, 2026 , C4 Therapeutics, Inc. (“ C4T ”) entered into a Research Collaboration and License Agreement ( the “ License Agreement ”) with F. Hoffmann-La Roche Ltd. (“ Roche Basel ”) and Hoffmann-La Roche Inc. (“ Roche US ”, and together with Roche Basel, “ Roche ”) to collaborate on the discovery, development and commercialization of degrader-antibody conjugates (" DACs ")”
C4 Therapeutics, Inc.: Stockholders approved an amendment to the Fifth Amended and Restated Certificate of Incorporation to increase authorized common shares from 150,000,000 to 300,000,000, which was filed and became effective on June 18, 2025 (effective 2025-06-18).
“On June 18, 2025 , the Company filed a Certificate of Amendment to the Company’s Fifth Amended and Restated Certificate of Incorporation (the “ Certificate of Amendment ”) with the Secretary of State of the State of Delaware and the Certificate of Amendment became effective on filing.”
Bruce Downey retired as Director at C4 Therapeutics, Inc..
“On April 10, 2025, Bruce Downey notified the Board of Directors (the “ Board ”) of C4 Therapeutics, Inc. (the “ Company ”) of his intention to retire from the Board and not to stand for reelection at the 2025 Annual Meeting of Stockholders.”
Steven L. Hoerter was appointed as Director at C4 Therapeutics, Inc..
“On November 19 , 2024 , the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Steven L. Hoerter as a director of the Company.”
Paige Mahaney was appointed as Chief Scientific Officer at C4 Therapeutics, Inc..
“On October 15, 2024, the Company announced the appointment of Paige Mahaney, Ph.D. as its Chief Scientific Officer, effective as of October 28, 2024.”
Stewart Fisher retired as Chief Scientific Officer at C4 Therapeutics, Inc..
“On October 11, 2024, Stewart Fisher, Ph.D. informed us of his intent to retire from the role of Chief Scientific Officer of C4 Therapeutics, Inc.”
Paige Mahaney was appointed as Chief Scientific Officer at C4 Therapeutics, Inc..
“On October 15, 2024, the Company announced the appointment of Paige Mahaney, Ph.D. as its Chief Scientific Officer, effective as of October 28, 2024.”
Stewart Fisher retired as Chief Scientific Officer at C4 Therapeutics, Inc..
“On October 1, 2024, Stewart Fisher, Ph.D. informed us of his intent to retire from the role of Chief Scientific Officer of C4 Therapeutics, Inc.”
Stephen Fawell was appointed as Director at C4 Therapeutics, Inc..
“On August 29, 2024, the Board of the Company, upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Stephen Fawell, Ph.D. as a director of the Company and a member of the Science and Technology Committee of the Board.”
Malcolm Salter resigned as Director at C4 Therapeutics, Inc..
“On August 28, 2024, Malcolm Salter informed the Board of Directors (the “Board”) of C4 Therapeutics, Inc. (the “Company”) of his intention to resign from the Board, effective upon the appointment of his successor.”
Bruce Downey departed as Director at C4 Therapeutics, Inc..
“Bruce Downey resigned as Chair of the Board, but will continue to serve as a member of the Board”
C4 Therapeutics, Inc. reported first quarter ended March 31, 2024 results: revenue $3.0 million.
“Total revenue for the first quarter of 2024 was $3.0 million”
C4 Therapeutics, Inc. entered into Research Collaboration and License Agreement with Merck KGaA, Darmstadt, Germany (operating as EMD Serono in U.S. and Canada) valued at upfront cash payment of $16.0 million; aggregate potential milestone payments of approximately $740 (effective 2024-03-01).
“On March 1, 2024 , C4 Therapeutics, Inc. (“ C4T ”) entered into a Research Collaboration and License Agreement (“ License Agreement ”) with Merck KGaA, Darmstadt, Germany (“ MKDG ”), which operates its healthcare business as EMD Serono in the U.S. and Canada, to exclusively discover two targeted protein degraders against critical oncogenic proteins that C4T has progressed within its internal discovery pipeline.”
C4 Therapeutics, Inc. reported financial results for the year ended December 31, 2023.
“On February 22, 2024, C4 Therapeutics, Inc. (the “ Company ”) issued a press release announcing its financial results and business highlights for the quarter and fiscal year ended December 31, 2023.”
C4 Therapeutics, Inc. announced a restructuring with charges of approximately $3 million (approximately 30% of the workforce or 45 positions).
“The employees impacted by the strategic imperatives and resulting Restructuring were notified on January 9, 2024 and represent approximately 30% of the workforce or 45 positions. The reductions will be substantially complete by the end of the first quarter of 2024. As a result of these changes, the Company estimates that it will incur charges of approximately $3 million.”
C4 Therapeutics, Inc. entered into License Agreement with Merck Sharp & Dohme LLC valued at up to approximately $2.5 billion in potential payments across the entire collaboration (effective 2023-12-11).
“C4 Therapeutics, Inc. (“ C4T ”) entered into a License and Collaboration Agreement (“ License Agreement ”) with Merck Sharp & Dohme LLC (“ Merck ”) to collaborate on the development and commercialization of degrader-antibody conjugates ( “ DACs ”: ), an emerging modality designed to selectively target and neutralize disease-causing proteins in cancer cells.”
Owen P. Hughes, Jr. was appointed as Director at C4 Therapeutics, Inc..
“On November 16, 2023, the Board of Directors (the “ Board ”) of C4 Therapeutics, Inc. (the “ Company ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Owen P. Hughes, Jr. as a director of the Company.”
C4 Therapeutics, Inc. reported financial results for the quarter ended September 30, 2023.
“On November 1, 2023, C4 Therapeutics, Inc. (the “ Company ”) issued a press release announcing its financial results and business highlights for the quarter ended September 30, 2023.”
Mark Mossler was appointed as Chief Accounting Officer at C4 Therapeutics, Inc..
“The Company has also appointed Mark Mossler as its Chief Accounting Officer and principal accounting officer, effective as of Monday September 18, 2023.”
Kendra Adams was appointed as Chief Financial Officer at C4 Therapeutics, Inc..
“On September 5, 2023, the Company announced the appointment of Kendra Adams as its Chief Financial Officer, Treasurer and principal financial officer, effective as of Monday September 18, 2023.”
Lauren White resigned as Chief Financial Officer at C4 Therapeutics, Inc..
“On August 30, 2023, Lauren White informed us of her intent to resign from C4 Therapeutics, Inc. (the “ Company ”), effective as of Friday September 15, 2023.”
C4 Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: revenue $2.7 million.
“for synovial sarcoma and SMARCB1-null solid tumors in the second half of 2023. SECOND QUARTER 2023 FINANCIAL RESULTS Revenue: Total revenue for the second quarter of 2023 was $2.7 million, compared to $13.8 million for the second quarter of 2022. The decrease in revenue was due to a reduction of revenue recognized for research activities under the Biogen and”
C4 Therapeutics, Inc. shareholders approved Amendment to Fifth Amended and Restated Certificate of Incorporation to limit liability of certain officers as permitted by Delaware law at the 2023-06-15 meeting.
“The stockholders of the Company approved the amendment to the Company’s Fifth Amended and Restated Certificate of Incorporation to limit the liability of certain officers of the Company as permitted by recent amendments to Delaware law.”
C4 Therapeutics, Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-15 meeting.
“The stockholders of the Company ratified the selection of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.”
C4 Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve compensation of named executive officers at the 2023-06-15 meeting.
“The stockholders of the Company cast a non-binding, advisory vote to approve the compensation of the Company’s named executive officers.”
C4 Therapeutics, Inc. shareholders approved Election of Class III directors at the 2023-06-15 meeting.
“The stockholders of the Company elected each of Andrew J. Hirsch, Utpal Koppikar and Malcom Salter as Class III directors, to hold office until the 2026 annual meeting of stockholders and until their respective successors have been duly elected and qualified or until his or her earlier resignation or removal.”
Leonard M.J. Reyno, M.D. was appointed as Chief Medical Officer at C4 Therapeutics, Inc..
“On June 20, 2023, C4 Therapeutics, Inc. (the “ Company ” or “ us ”), announced the appointment of Leonard M.J. Reyno, M.D. as its Chief Medical Officer, effective as of July 10, 2023.”
C4 Therapeutics, Inc. entered into Stock Purchase Agreement with Betta Pharmaceuticals Co., Ltd. and Betta Investment (Hong Kong) Limited valued at aggregate purchase price of approximately $25.0 million (effective 2023-05-29).
“On May 29, 2023 and in connection with the execution of the License Agreement, C4T, Betta Pharma, and Betta Investment (Hong Kong) Limited (“ Betta Investment ”), an affiliate of Betta Pharma, entered into a Stock Purchase Agreement (the “ Stock Purchase Agreement ” and together with the License Agreement, the “ Betta Agreements ”), pursuant to which Betta Investment agreed to purchase 5,567,928 shares of C4T common stock (the “ Shares ”) for an aggregate purchase price of approximately $25.0 million”
C4 Therapeutics, Inc. entered into License Agreement with Betta Pharmaceuticals Co., Ltd. valued at upfront cash payment of $10.0 million and up to $357.0 million in aggregate milestone payments (effective 2023-05-29).
“On May 29, 2023 , C4 Therapeutics, Inc. (“ C4T ”) entered into a License and Collaboration Agreement (“ License Agreement ”) with Betta Pharmaceuticals Co., Ltd. (“ Betta Pharma ”) to collaborate on the development and commercialization of CFT8919”
C4 Therapeutics, Inc. reported the first quarter ended March 31, 2023 results: revenue $3.8 million, net income $34.8 million, EPS $0.71.
“will participate in the Jefferies Global Healthcare Conference in New York. FIRST QUARTER 2023 FINANCIAL RESULTS Revenue: Total revenue for the first quarter of 2023 was $3.8 million, compared to $7.7 million for the first quarter of 2022. Total revenue reflects revenue recognized under collaboration agreements with Roche, Biogen, and Calico. Research and”
C4 Therapeutics, Inc. reported the year ended December 31, 2022 results: revenue $31.1 million, net income $128.2 million, EPS $2.62.
“Revenue: Total revenue for the year ended December 31, 2022 was $31.1 million, compared to $45.8 million for the year ended December 31, 2021.”
Adam S. Crystal resigned as Chief Medical Officer at C4 Therapeutics, Inc..
“On January 30, 2023, Adam S. Crystal, M.D., Ph.D., informed us of his intent to resign from his position as the Chief Medical Officer of C4 Therapeutics, Inc.”
C4 Therapeutics, Inc. reported third quarter ended September 30, 2022 results: revenue $6.8 million, net income $32.0 million, EPS $0.65.
“will participate in a fireside chat at the Evercore ISI HealthCONx Conference. THIRD QUARTER 2022 FINANCIAL RESULTS Revenue: Total revenue for the third quarter of 2022 was $6.8 million, compared to $8.5 million for the third quarter of 2021. Total revenue reflects revenue recognized under collaboration agreements with Roche, Biogen, and Calico. Research and”
Laura Bessen, M.D. was elected as Director at C4 Therapeutics, Inc..
“On July 29, 2022, the Company’s Board of Directors (the “ Board ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Donna Grogan, M.D. and Laura Bessen, M.D, as directors of the Company.”
Donna Grogan, M.D. was elected as Director at C4 Therapeutics, Inc..
“On July 29, 2022, the Company’s Board of Directors (the “ Board ”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, elected Donna Grogan, M.D. and Laura Bessen, M.D, as directors of the Company.”
Alain J. Cohen departed as director at C4 Therapeutics, Inc..
“On June 15, 2022, Alain J. Cohen notified the Board of Directors (the “ Board ”) of C4 Therapeutics, Inc. (the “ Company ”) of his withdrawal as a director nominee for re-election at the 2022 Annual Meeting of Stockholders.”
Elena Prokupets resigned as Director at C4 Therapeutics, Inc..
“Elena Prokupets, Ph.D., resigned as a director and as a member of the Audit, Compensation and Nominating and Corporate Governance Committees of the Board.”
Utpal Koppikar was elected as Director at C4 Therapeutics, Inc..
“elected Utpal Koppikar as a director effective immediately and as chair of the Audit Committee”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.